For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| General and administrative costs (includes 1,388,322 and 418,422 of stock-based compensation, respectively) | 4,852,702 | 2,846,557 | ||
| Research and development costs | 254,919 | 726,232 | ||
| Total costs and expenses | 5,107,621 | 3,572,789 | ||
| Loss from operations | -5,107,621 | -3,572,789 | ||
| Interest income | 7,388 | 7,048 | ||
| Interest expense | 9,158 | 16,821 | ||
| Realized loss on digital assets | 904,394 | - | ||
| Foreign currency gain (loss) | 525 | - | ||
| Other income | 3,740 | - | ||
| Net loss | -6,009,520 | - | ||
| Foreign currency gain (loss) | - | -3,403 | ||
| Series b convertible preferred stock 8 cumulative dividend | 69,073 | - | ||
| Net loss attributable to common stockholders | -6,078,593 | -3,585,965 | ||
| Basic EPS | - | -1.59 | ||
| Diluted EPS | -1.26 | -1.59 | ||
| Basic Average Shares | - | 2,249,290 | ||
| Diluted Average Shares | 4,840,731 | 2,249,290 | ||
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)